Skip to main content
OpenTrials
Completed

NCT Number: NCT05539144

A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in IMRT for Head and Neck Cancer

The investigators tries a new method to delineating the oral cavity, oropharynx, larynx and hypopharynx, and use the head-and-neck region to test whether the method can to create a good IMRT plan, and alleviate the oral radiation injury, reduce the incidence of adverse reactions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Head and Neck Cancer Head and Neck Neoplasms Neoplasms Neoplasms by Site Oropharynx Abnormality Radiation Injuries Radiotherapy Radiotherapy; Adverse Effect Wounds and Injuries

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine

Shijiazhuang, Hebei, 050011, China

About this study

Purpose: To assess the dosimetric effect of new delineation approach for oral cavity, oropharynx, larynx and hypopharynx in intensity-modulated radiotherapy(IMRT) treatment planning for head and neck cancer.

Methods: Twenty head and neck cancer patients were treated by IMRT. Target volumes and several organs at risk were delineated with Corvus6．3 treatment planning system. An investigative IMRT plan was generated based on a standard treatment planning protocol, but used a new delineation approach for oral cavity, oropharynx, larynx and hypopharynx. Plans were exported to treatment planning system for quantitative analysis of dose volume parameters. Variables assessed included: maximum oral cavity, oropharynx, larynx and hypopharynx dose, equivalent uniform dose of the oral cavity, oropharynx, larynx and hypopharynx (EUD), mean oral cavity, oropharynx, larynx and hypopharynx dose, mean organs at risks (OARs) doses, and dose homogeneity inside the target volumes.

.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with previously untreated of the head and neck cancer who received definitive IMRT at our institution

Exclusion criteria

-

Treatment and study plan

"Oropharyngeal mucosa"

Radiation

"Oropharyngeal mucosa" was delineated as OARs and limiting its dose

oropharynx

Radiation

oropharynx was delineated as OARs and limiting its dose

oropharynx and "oropharyngeal mucosa"

Radiation

oropharynx and "oropharyngeal mucosa"were delineated as OARs and limiting its dose

Primary outcomes

  1. Dose distribution

    Time frame: through study completion, an average of 1 year

    maximum oral cavity, oropharynx, larynx and hypopharynx dose, equivalent uniform dose of the oral cavity, oropharynx, larynx and hypopharynx (EUD), mean oral cavity, oropharynx, larynx and hypopharynx dose, mean organs at risks (OARs) doses, and dose homogeneity inside the target volumes.

Sponsors and collaborators

Lead sponsor

Hebei Provincial Hospital of Traditional Chinese Medicine

Other Gov

Registry information

Official study title

A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in Intensity-modulated Radiation Treatment for Head and Neck Cancer

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Sep 14, 2022
Registry last updated
May 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.